A Clinical Study on the Effect of Metronidazole Suppositories Combined with Yuexiao Gel on Reducing the Recurrence Rate of Bacterial Vaginosis

A Clinical Study on the Effect of Metronidazole Suppositories Combined with Yuexiao Gel on Reducing the Recurrence Rate of Bacterial Vaginosis - The Combined Use of Metronidazole Suppository and Vaginal Antibacterial Gel for the Treatment of Bacterial Vaginosis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600124081

Enrollment

Unknown

Registered

2026-05-07

Start date

2023-04-25

Completion date

Unknown

Last updated

2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacterial Vaginosis

Interventions

Combinated intervention group (Metronidazole Suppository and YueXiao Antibacterial Gel group):Begin treatment with YueXiao Antimicrobial Gel 1–3 days after completion of standard Metronidazole Suppo

Intervention group (Vaginal Antibacterial Gel group):Each night before bed, clean the vulva with warm water, then apply YueXiao Antibacterial Gel. Squeeze approximately one-third of the tube’s content

Control group (Metronidazole Suppository group):Each night before bedtime, clean the vulva with warm water and then insert one metronidazole suppository. Use a clean finger cot to insert the supposito

Eligibility

Sex/Gender

Female

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with bacterial Vaginosis according to the Amsel criteria; 2. Aged 20-50 years; 3. All patients attended their follow-up appointments and demonstrated good compliance. Amsel criteria: Three of the following four characteristics must be present, with a positive clue cell test being a mandatory requirement: (1) Positive amine test, i.e., the addition of 10% KOH to vaginal secretions produces a fishy odor; (2) Vaginal pH > 4.50; (3) Increased vaginal discharge that is thin, homogeneous, and malodorous; (4) Positive for clue cells.

Exclusion criteria

Exclusion criteria: 1. Other uncomplicated vaginal or vulvar infections; 2. Patients requiring long-term medication or with a history of severe illness; 3. Patients who are breastfeeding, planning to become pregnant, or currently pregnant; 4. Patients with severe heart, liver, or kidney damage; 5. Patients who have already received relevant treatment that may affect the study outcomes; 6. Patients with mental disorders; 7. Patients who were lost to follow-up.

Design outcomes

Primary

Measure	Time frame
Cure rate;Overall efficiency rate;Adverse reactions;	—

Secondary

Measure	Time frame
Nugent score;Vaginal microecology;Recurrence rate 3 months after treatment;	—

Countries

China

Contacts

Public ContactXuemei Qing

Chengdu Qingbaijiang District People’s Hospital, Sichuan

qingxuemei1988@outlook.com+86 159 2840 3205

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 16, 2026